Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

541. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice

Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice O'Byrne P, Cuddy L, Taylor D W, Birch S, Morris J, Syrotuik J Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Inhaled corticosteroids (budesonide) for the prevention of asthmatic attacks and the reduction of associated symptoms. Type of intervention Secondary prevention and treatment. Economic study type Cost-benefit analysis. Study population Adults aged 18 years

1996 NHS Economic Evaluation Database.

542. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. (Abstract)

Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Preliminary studies suggested that mycophenolate mofetil (MMF), which inhibits proliferation of T and B cells, may reduce the frequency of acute rejection after renal transplantation. Our randomised, double-blind, multicentre, placebo-controlled study compared the efficacy and safety of MMF with placebo (...) for prevention of acute rejection episodes after first or second cadaveric renal allograft transplantation. 491 patients were enrolled; 166 were assigned placebo, 165 MMF 2 g, and 160 MMF 3 g. Patients also received cyclosporin and corticosteroids. Significantly fewer (p < or = 0.001) patients had biopsy-proven rejection or withdrew early from the trial (for any reason) during the first 6 months after transplantation with MMF 2 g (30.3%) or 3 g (38.8%) than with placebo (56.0%). The corresponding percentages

1995 Lancet Controlled trial quality: predicted high

543. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature

of related interest 1. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45. 2. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-1303. Indexing Status Subject indexing assigned by NLM MeSH Adrenal Cortex Hormones /therapeutic use; Humans; Randomized Controlled Trials as Topic; Research Design; Risk; Sepsis /drug therapy /mortality; Shock, Septic /drug therapy /mortality; Treatment Outcome (...) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Cronin L, Cook D J, Carlet J, Heyland D K, King D, Lansang M A, Fisher C J Authors' objectives To determine the effect of corticosteroid therapy on morbidity and mortality in patients with sepsis. Searching MEDLINE

1995 DARE.

544. A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica

that confirmation of the findings and the safety of epidural steroids should be addressed in a further study of appropriate design and adequate size. Bibliographic details Watts R W, Silagy C A. A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica. Anaesthesia and Intensive Care 1995; 23(5): 564-569 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adrenal Cortex Hormones /administration & Humans; Injections, Epidural; Odds Ratio; Randomized Controlled Trials (...) A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica Watts R W, Silagy C A Authors' objectives To investigate the efficacy of epidural corticosteroids in the treatment of sciatica. Searching MEDLINE was searched from 1966 to the present. The terms searched were: 'epidural, caudal

1995 DARE.

545. Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature

Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1995 PedsCCM Evidence-Based Journal Club

546. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. (Abstract)

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Guidelines on asthma management recommend that in patients who still have symptoms on treatment with low-dose inhaled corticosteroids the first step should be an increase in inhaled corticosteroid dose. The addition of long-acting inhaled beta 2-adrenoceptor agonists is another option. We have compared these two strategies

1994 Lancet Controlled trial quality: predicted high

547. Lack of effect of intraarticular corticosteroids for chronic pain in the cervical zygapophyseal joints. (Abstract)

Lack of effect of intraarticular corticosteroids for chronic pain in the cervical zygapophyseal joints. Chronic pain in the cervical zygapophyseal joints is a common problem after a whiplash injury. Treatment with intraarticular injections of corticosteroid preparations has been advocated, but the value of this approach has not been established. We compared the efficacy of a depot injection of a corticosteroid preparation with the efficacy of an injection of a local anesthetic agent in patients (...) percent of the preinjection level. The time from treatment to a 50 percent return of pain was compared in the two groups with the use of a survival analysis.Less than half the patients reported relief of pain for more than one week, and less than one in five patients reported relief for more than one month, irrespective of the treatment received. The median time to a return of 50 percent of the preinjection level of pain was 3 days in the 21 patients in the corticosteroid group and 3.5 days in the 20

1994 NEJM Controlled trial quality: uncertain

548. A meta-analysis of the effect of oral and inhaled corticosteroids on growth

and Clinical Immunology 1994; 93(6): 967-976 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones /administration & Age Factors; Asthma /drug therapy; Beclomethasone /adverse effects; Child; Growth /drug effects; Humans; dosage /adverse effects AccessionNumber 11995003418 Date bibliographic record published 31/07/1996 Date abstract record published 31/07/1996 Record Status This is a critical abstract of a systematic review (...) A meta-analysis of the effect of oral and inhaled corticosteroids on growth A meta-analysis of the effect of oral and inhaled corticosteroids on growth A meta-analysis of the effect of oral and inhaled corticosteroids on growth Allen D B, Mullen M, Mullen B Authors' objectives To assess the effect of inhaled and oral corticosteroids on linear growth, i.e. height. Searching The authors state that an 'exhaustive literature search of leading medical journals' was performed from 1956 to 1993

1994 DARE.

549. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. (Abstract)

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. Optic neuritis is often the first clinical manifestation of multiple sclerosis, but little is known about the effect of corticosteroid treatment for optic neuritis on the subsequent risk of multiple sclerosis.We conducted a multicenter study in which 389 patients with acute optic neuritis (and without known multiple sclerosis) were randomly assigned

1993 NEJM Controlled trial quality: predicted high

550. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. (Abstract)

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. Prolonged corticosteroid therapy increases the risk of osteoporosis and fracture. We studied whether corticosteroid-induced osteoporosis could be prevented by treatment with calcium, calcitriol (1,25-dihydroxyvitamin D3), and calcitonin.One hundred three patients starting long-term corticosteroid therapy were randomly assigned to receive 1000 mg of calcium per day orally and either calcitriol (0.5 (...) to 1.0 microgram per day orally) plus salmon calcitonin (400 IU per day intranasally), calcitriol plus a placebo nasal spray, or double placebo for one year. Data on treatment efficacy were available for 92 of these patients. Bone density was measured every four months for two years by photon absorptiometry. There were no significant differences between groups with respect to age, underlying disease, initial bone density, or corticosteroid dose during the first year.Calcitriol (mean dose, 0.6

1993 NEJM Controlled trial quality: uncertain

551. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. (Abstract)

Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. The treatment of chronic severe asthma is unsatisfactory for many patients. In a randomised, double-blind, placebo-controlled, crossover trial we have tested whether cyclosporin, which is thought to act primarily by inhibition of T lymphocyte activation, improves lung function in corticosteroid-dependent asthmatics. After a 4-week run-in period, 33 patients with longstanding asthma (mean duration 27 years), and who had (...) required continuous oral corticosteroids for a mean of 9.3 years, were randomised to receive either cyclosporin (initial dose 5 mg/kg per day) or placebo for 12 weeks, crossing over after a 2-week washout period. Mean baseline forced expiratory volume in 1 s (FEV1) was 60.1% of the predicted value. 2 patients failed to complete the protocol and 1 withdrew because of hypertrichosis. Cyclosporin therapy resulted in a mean increase above placebo of 12.0% in morning peak expiratory flow rate (PEFR; p less

1992 Lancet Controlled trial quality: predicted high

552. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. (Abstract)

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. The use of corticosteroids to treat optic neuritis is controversial. At 15 clinical centers, we randomly assigned 457 patients with acute optic neuritis to receive oral prednisone (1 mg per kilogram of body weight per day) for 14 days; intravenous methylprednisolone (1 g per day) for 3 days, followed by oral prednisone (1 mg per kilogram per day) for 11 days; or oral

1992 NEJM Controlled trial quality: predicted high

553. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. (Abstract)

Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. In children with corticosteroid-responsive nephrotic syndrome who are dependent on high-dose prednisolone, alkylating therapy often fails to maintain a remission, and long-term immunosuppression may be hazardous. An alternative approach to treatment is to use an immunostimulant such as levamisole. 61 children with frequently relapsing corticosteroid sensitive and dependent (...) nephrotic syndrome were randomly allocated to receive levamisole, 2.5 mg/kg on alternate days (31 patients) or placebo (30 patients) for a maximum of 112 days. After entry to the trial, prednisolone was progressively reduced and was stopped by 56 days. The two groups were well matched for age and sex distribution, indices of corticosteroid toxicity, and previous alkylating therapy. 14 patients in the levamisole group and 4 in the placebo group remained in remission at 112 days (log rank analysis p less

1991 Lancet Controlled trial quality: uncertain

554. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. (Abstract)

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. The presence of airway inflammation even in mild asthma points to the potential value of antiinflammatory therapy. We compared the effect of an inhaled corticosteroid, budesonide, with that of an inhaled beta 2-agonist, terbutaline, in the long-term treatment of newly detected asthma.We studied 103 patients (29 male and 74 female patients 15 to 64 years old) in whom asthma had

1991 NEJM Controlled trial quality: uncertain

555. A controlled trial of corticosteroid injections into facet joints for chronic low back pain. (Abstract)

A controlled trial of corticosteroid injections into facet joints for chronic low back pain. Chronic low back pain is a common problem with many treatments, few of which have been rigorously evaluated. This randomized, placebo-controlled trial was designed to evaluate the efficacy of injections of corticosteroid into facet joints to treat chronic low back pain.Patients with chronic low back pain who reported immediate relief of their pain after injections of local anesthetic into the facet

1991 NEJM Controlled trial quality: predicted high

556. [Treatment of peripheral paresis-paralysis of the facial nerve using corticosteroids]. (Abstract)

[Treatment of peripheral paresis-paralysis of the facial nerve using corticosteroids]. The study comprised 113 patients with Bell's paresis-paralysis of the facial nerve. This group was considered as experimental while the control group involved patients with the same disease treated with oral corticosteroids. In both groups physical therapy has been applied from the very beginning of therapy. The results of the study have shown that in the group of patients treated with local corticosteroids

1990 Vojnosanitetski pregled

557. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. (Abstract)

Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. Preliminary reports suggest that patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia may benefit from the addition of corticosteroid treatment to antibiotic therapy.We conducted a double-blind, placebo-controlled trial to assess the efficacy of adjunctive corticosteroids in patients (...) no significant differences in base-line clinical or laboratory measures between the two treatment groups. Of 12 patients treated with corticosteroids, 9 (75 percent) survived until hospital discharge, as compared with only 2 of 11 placebo recipients (18 percent) (P less than 0.008). Respiratory failure developed in nine placebo recipients, as compared with only three patients treated with corticosteroids (P less than 0.008). No patient required the interruption or discontinuation of corticosteroid

1990 NEJM Controlled trial quality: predicted high

558. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. Full Text available with Trip Pro

A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. Pneumocystis carinii pneumonia remains a common cause of serious morbidity and mortality in patients with the acquired immunodeficiency syndrome (AIDS). The extensive lung injury that accompanies pneumocystis-associated respiratory failure and the reports of clinical benefit from the use of adjunctive (...) corticosteroids provided the rationale for this prospective multicenter trial.A total of 333 patients with AIDS and pneumocystis pneumonia received standard treatment and were randomly assigned to receive either corticosteroids (beginning with the equivalent of 40 mg of prednisone twice daily) or no additional therapy. The primary end points in this unblinded trial were the occurrence of respiratory failure (hypoxemia ratio [partial pressure of arterial oxygen divided by fraction of inspired oxygen] less than

1990 NEJM Controlled trial quality: predicted high

559. A controlled trial of corticosteroids in children with corrosive injury of the esophagus. (Abstract)

A controlled trial of corticosteroids in children with corrosive injury of the esophagus. It is controversial whether treatment with corticosteroids reduces stricture formation in the esophagus after the ingestion of caustic material.We conducted a prospective study over an 18-year period in which 60 children (median age, 2 years) with esophageal injury from the ingestion of caustic material were assigned randomly to treatment either with or without corticosteroids. The corticosteroids were (...) given initially as prednisolon (2 mg per kilogram of body weight per day intravenously) and then as prednisone orally to complete a three-week course. All patients were evaluated by esophagoscopy within 24 hours of the ingestion. Those with moderate or severe esophageal injury had repeat esophagoscopy and barium swallow at follow-up.Esophageal strictures developed in 10 of the 31 children treated with corticosteroids and in 11 of the 29 controls (P not significant). Four children in the steroid

1990 NEJM Controlled trial quality: uncertain

560. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. (Abstract)

Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. We studied the effects of radioiodine treatment of hyperthyroidism due to Graves' disease on Graves' ophthalmopathy and the possible protective role of corticosteroids. Between June 1985 and June 1988, 26 patients were randomly assigned to treatment with radioiodine alone (group 1) and 26 to treatment with this agent and concomitant administration of systemic prednisone (...) in group 1 (P less than 0.005) and decreased from 2.2 to 1.3 in group 2 (P less than 0.05). We conclude that systemic corticosteroid treatment prevents the exacerbations of Graves' ophthalmopathy that occur after radioiodine therapy in a substantial proportion of patients with hyperthyroidism who have some degree of ocular involvement before treatment.

1989 NEJM Controlled trial quality: uncertain